New drug delivery method promises long-lasting glaucoma relief
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...
Healio14h
Lumevoq for LHON yields sustained visual acuity improvements at 5 years in phase 3 trial
A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...
Scientists Unveil Safer Way To Treat Inflammatory Eye Diseases
A study found that injecting mesenchymal stem cells into periocular tissue effectively reduces eye inflammation without ...
Pharmabiz4d
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema
Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...
Hosted on MSN4d
Regeneron’s macular oedema therapy shows promise in Phase III trial
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
modernretina4d
Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg
Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.
PipelineReview.com4d
Bayer files for approval of extended 6-month treatment interval for Eylea™ 8 mg in the EU
Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...